LENSAR, Inc.
No enriched coverage for $LNSR in the last 7 days.
No SEC Form 4 filings for $LNSR in the last 30 days.
See all $LNSR insider activity →LENSAR (LNSR) reported Q2 2026 revenue of $16.5M, up 18%, with recurring revenue growing 20% to $13.7M. Procedure revenue increased 23% to $10.2M, and adjusted EBITDA improved. The company expanded its installed base and market share, with ALLY systems accounting for nearly half of global installations. Management highlighted long-term growth metrics and international expansion plans.
LENSAR, Inc. reported Q2 2026 results on an earnings call after ending the Alcon merger. Management said revenue rose 18%, driven by 23% higher procedure revenue, and adjusted EBITDA hit its strongest level. Recurring revenue was 83% of total. Gross margin was 59% including a $1.1m tariff refund; normalized was 52%. Backlog was 13 ALLY systems.
The article lists Thursday premarket movers, citing large early price swings in multiple stocks. Gainers include FGI Industries (FGI) up 91% to $9.24, Accelerant Holdings (ARX) up 45% to $19.67, and Harmonic (HLIT) up 23% to $14.74. Losers include Cellebrite DI (CLBT) down 28% to $11.01 and Securitize (SECZ) down 21% to $6.25.
Recent LNSR coverage spans earnings, financial news and market movers.
Positive earnings surprise may support short‑term price upside.
The call highlights improving profitability and expanding ALLY installed base, but also flags near-term volume seasonality and construction-driven backlog timing risk.
The stock may see elevated volatility and trader attention at the open.
The earnings beat plus first positive net income and accelerating recurring revenue are the immediate drivers behind the pre-market surge.
The filing discloses accelerating recurring/procedure growth, a growing installed base, and improved profitability, which can re-rate near-term demand and cash burn expectations.
AlphAI scores every news story that mentions LNSR with an AI model for sentiment and relevance, and aggregates insider trades from LENSAR, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
LENSAR (LNSR) reported Q2 2026 revenue of $16.5M, up 18%, with recurring revenue growing 20% to $13.7M. Procedure revenue increased 23% to $10.2M, and adjusted EBITDA improved. The company expanded its installed base and market share, with ALLY systems accounting for nearly half of global installations. Management highlighted long-term growth metrics and international expansion plans.
3 min readLENSAR, Inc. reported Q2 2026 results on an earnings call after ending the Alcon merger. Management said revenue rose 18%, driven by 23% higher procedure revenue, and adjusted EBITDA hit its strongest level. Recurring revenue was 83% of total. Gross margin was 59% including a $1.1m tariff refund; normalized was 52%. Backlog was 13 ALLY systems.
7 min readThe article lists Thursday premarket movers, citing large early price swings in multiple stocks. Gainers include FGI Industries (FGI) up 91% to $9.24, Accelerant Holdings (ARX) up 45% to $19.67, and Harmonic (HLIT) up 23% to $14.74. Losers include Cellebrite DI (CLBT) down 28% to $11.01 and Securitize (SECZ) down 21% to $6.25.
3 min readInvesting.com reports LENSAR (LNSR) shares rose 16.1% in pre-open after Q2 results beat expectations. The company posted EPS of $0.10 vs consensus -$0.21 and revenue of $16.5M vs $15M. It cited 18% YoY revenue growth, 20% recurring revenue growth, and first positive net income, with 10 ALLY systems placed.
3 min readLENSAR, Inc. (LNSR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LENSAR ® Reports Second Quarter 2026 Results and Provides Business Update 10 ALLY Robotic Cataract Laser Systems ® (“ALLY System”) Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026 Second Quarter Recurring Revenue was $13.7 million Tot
6 min readLENSAR, Inc. (LNSR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 4, 2026, LENSAR, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). At the close of business on June 10, 2026, the record date for the Annual Meeting (the “Record Date”), 12
2 min readLensar reported Q4 2025 revenue of $16 million, down 4% mainly from lower system sales, including weaker sales outside the U.S. The company placed 15 ALLY systems (12 U.S., 1 outside) and grew its installed base to just over 200 ALLY systems (+48%). Recurring revenue rose 17% to $12.7 million (79% of Q4 revenue). Gross margin was 43% ($6.9 million). Management said the Alcon acquisition termination restored independence and full title to a $10 million deposit; 2026 cash operating expenses are ex
6 min readLENSAR, Inc.'s CEO, Nicholas T. Curtis, filed a Form 4 detailing an administrative change related to vested restricted stock units. He paid cash to cover tax withholdings, resulting in no actual transfer of shares and his direct holdings remaining at 992,096 common stock shares. This transaction is noted as neutral in impact and sentiment, as no shares were bought or sold.
2 min readLENSAR, Inc. (NASDAQ: LNSR) has filed an Amendment No. 1 to its annual report (Form 10-K/A) to include comprehensive Part III disclosures, which detail information on directors, executive compensation, ownership, related-party transactions, and auditor fees for the fiscal year ended December 31, 2025. The filing clarifies that North Run Capital and affiliates beneficially own approximately 55% of LENSAR's common stock and hold 45.1% of combined voting power, stemming from a $20.0 million investment in Series A Convertible Preferred Stock and warrants made in 2024. The amendment also outlines the 2025 compensation for key executives, with CEO Nicholas T. Curtis receiving over $2.3 million.
3 min read18 ALLY Robotic Cataract Laser Systems™ ( "ALLY Systems" ) placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June ...
3 min read
